Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Canada Regulation BioPharmaceutical

Canada Wants More Agility And Alignment In Drug Regulations

  • News

Executive Summary

The Canadian regulator has proposed several changes to current drug regulations to deliver on its modernization commitments and leverage long-standing policies and practices.

You may also be interested in...



Canada Addresses Diversity In Clinical Trials With New Rule For Drug Filings

Health Canada wants drug sponsors to start answering questions relating to disaggregated data for sex, age and race.

New Canadian Rule Allows Rolling Data Submissions For COVID-19 Drugs, Vaccines

The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.

Singapore To Require GMP Evidence On Chemical Substance Drug Manufacturers

Singapore is taking steps to align good manufacturing practice requirements for chemical and biologic drug substance manufacturers and has rolled out a one-year transition plan for compliance.

Table

View full table

Topics

Tags:
Canada Regulation BioPharmaceutical
Latest Headlines

UK Govt Under Fire From Pharma Industry Over Statutory Pricing Scheme Changes

US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

See All
UsernamePublicRestriction

Register

PS147490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By